Company | Date | Price Target | Rating | Analyst |
---|---|---|---|---|
7/15/2024 | $50.00 → $37.00 | Equal-Weight → Underweight | Morgan Stanley | |
6/11/2024 | $46.00 | Neutral → Buy | BTIG Research | |
6/3/2024 | $100.00 | Mkt Perform → Outperform | Barrington Research | |
3/11/2024 | $30.00 → $50.00 | Hold → Buy | Stifel | |
12/5/2023 | Buy → Hold | Needham | ||
12/4/2023 | $35.00 | Equal-Weight | Morgan Stanley | |
9/15/2023 | Buy → Hold | The Benchmark Company | ||
8/3/2023 | $77.00 → $48.00 | Buy → Hold | Canaccord Genuity |
SC 13G/A - Dolby Laboratories, Inc. (0001308547) (Subject)
SC 13G/A - STAAR SURGICAL CO (0000718937) (Subject)
SC 13G/A - STAAR SURGICAL CO (0000718937) (Subject)
4 - STAAR SURGICAL CO (0000718937) (Issuer)
4 - Dolby Laboratories, Inc. (0001308547) (Issuer)
4 - STAAR SURGICAL CO (0000718937) (Issuer)
New Appointments Underscore Commitment to Driving Innovation and Industry-Leading Growth STAAR Surgical Company (NASDAQ:STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced Nancy Sabin has been named Chief Marketing Officer and Nathaniel Sisitsky has been named General Counsel. Both will serve on the Company's executive committee and report to Tom Frinzi, STAAR Surgical's President and CEO. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240501408389/en/Nancy Sabin, Chief Marketing Officer, STAAR Surgical (Photo:
STAAR Surgical Company (NASDAQ:STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (ICL) for myopia, astigmatism and presbyopia, today announced the appointment of Arthur Butcher, Executive Vice President and Group President, MedSurg and Asia Pacific for Boston Scientific, and Wei Jiang, retired Executive Vice President and President of Bayer Pharmaceuticals Region China & APAC, to its Board of Directors, effective March 12, 2024. "Art Butcher and Wei Jiang are seasoned executives with broad leadership experience built over decades at two of the most highly regarded global companies in the healthcare industry," said Aimee Weisner, Chair
STAAR Surgical Company (NASDAQ:STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (ICL) for myopia, astigmatism and presbyopia, today announced the appointment of Lilian Zhou to its Board of Directors, effective December 4, 2023. "We welcome Lilian Zhou as a new member to our Board of Directors. Lilian is an accomplished investment portfolio manager who worked at highly regarded Wall Street investment institutions before founding her own firm a decade ago," said Aimee Weisner, Chair of the Nominating and Governance Committee of STAAR Surgical's Board of Directors. "We look forward to Lilian's contributions as a former institutional shar
SAN FRANCISCO, Aug. 7, 2024 /PRNewswire/ -- Dolby Laboratories, Inc. (NYSE:DLB) today announced the company's financial results for the third quarter of fiscal 2024. "Our third quarter results were in line with expectations," said Kevin Yeaman, President and CEO, Dolby Laboratories. "This quarter we continued to build momentum for the content available in Dolby Vision and Dolby Atmos, especially in sports, with viewers around the world enjoying the T20 Cricket World Cup, UEFA EURO 2024, Wimbledon, the NHL and NBA post seasons and right now, the Olympics in Dolby." Third Quarte
STAAR Surgical Company (NASDAQ:STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that it will release financial results for the second quarter ended June 28, 2024, on Wednesday, August 7, 2024, after the market close. Event: STAAR Surgical 2Q 2024 Financial Results Webcast Date: Wednesday, August 7, 2024 Time: 4:15 p.m. ET / 1:15 p.m. PT Location: https://staar-surgical-2q24-earnings.open-exchange.net/ STAAR will also host an earnings webcast on Wednesday, August 7 at 4:15 p.m. Eastern / 1:15 p.m. Pacific to discuss its financial results and operational progress. The
SAN FRANCISCO, July 8, 2024 /PRNewswire/ -- Dolby Laboratories, Inc. (NYSE:DLB), a leader in immersive entertainment experiences, will release financial results for the third quarter (Q3) after the close of regular trading on Wednesday, August 7, 2024. Members of Dolby management will lead a conference call open to all interested parties to discuss Q3 financial results for Dolby Laboratories at 2:00 p.m. PT (5:00 p.m. ET) on Wednesday, August 7, 2024. Access to the teleconference will be available at http://investor.dolby.com or by dialing 1-888-210-2212 (+1-646-960-0390 for i
4 - STAAR SURGICAL CO (0000718937) (Issuer)
4 - Dolby Laboratories, Inc. (0001308547) (Issuer)
4 - STAAR SURGICAL CO (0000718937) (Issuer)
Morgan Stanley downgraded STAAR Surgical from Equal-Weight to Underweight and set a new price target of $37.00 from $50.00 previously
BTIG Research upgraded STAAR Surgical from Neutral to Buy and set a new price target of $46.00
Barrington Research upgraded Dolby Labs from Mkt Perform to Outperform and set a new price target of $100.00
BTIG analyst Ryan Zimmerman maintains Staar Surgical (NASDAQ:STAA) with a Buy and raises the price target from $46 to $53.
Staar Surgical (NASDAQ:STAA) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 0 2 1 0 Last 30D 0 0 0 1 0 1M Ago 0 0 0 0 0 2M Ago 1 0 0 0 0 3M Ago 1 0 2 0 0 The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $44.2, a high estimate of $55.00, and a low estimate of $37.00. Experiencing a 2.86% decline, the current average
8-K - Dolby Laboratories, Inc. (0001308547) (Filer)
10-Q - Dolby Laboratories, Inc. (0001308547) (Filer)
8-K - Dolby Laboratories, Inc. (0001308547) (Filer)
FanDuel, ITV, Las Vegas Sands, NASCAR, NFL, and others are leveraging these latest solutions to increase engagement while improving the streaming and iGaming experiences of their audiences AMSTERDAM, Sept. 13, 2024 /PRNewswire/ -- Dolby Laboratories, Inc. (NYSE: DLB), a leader in immersive entertainment, today unveiled a new comprehensive range of cloud video products and solutions supporting real-time interactive streaming. This comes on the heels of Dolby's recent acquisition of THEO Technologies, a leading provider of high-quality video streaming tools embraced by top sports, media, and entertainment companies worldwide.
SAN FRANCISCO, Sept. 5, 2024 /PRNewswire/ -- Dolby Laboratories, Inc. (NYSE:DLB) today announced that Kevin Yeaman, President and CEO, will host a fireside chat at the Goldman Sachs Communacopia and Technology Conference in San Francisco, California on Thursday, September 12, 2024, at 8:50 AM PT (11:50 AM ET). A live webcast and replay of the event will be available at http://investor.dolby.com. About Dolby Laboratories Dolby Laboratories (NYSE:DLB) is based in San Francisco, California with offices around the globe. From movies and TV shows, to apps, music, sports, and gaming
SAN FRANCISCO, Aug. 13, 2024 /PRNewswire/ -- Dolby Laboratories, Inc. (NYSE:DLB) today announced that Robert Park, Chief Financial Officer, will host a fireside chat at the Rosenblatt Technology Summit virtually on Tuesday, August 20, 2024, at 3:00 PM ET. A live webcast and replay of the event will be available at http://investor.dolby.com. About Dolby Laboratories Dolby Laboratories (NYSE:DLB) is based in San Francisco, California with offices around the globe. From movies and TV shows, to apps, music, sports, and gaming, Dolby transforms the science of sight and sound into s